EYEN - Eyenovia Inc Stock Price, Fair Value and News

0.75USD-0.07 (-8.54%)Market Closed

Market Summary

USD0.75-0.07

Market Closed

-8.54%

EYEN Stock Price

View Fullscreen

EYEN RSI Chart

EYEN Valuation

Market Cap

38.2M

Price/Earnings (Trailing)

-1.18

Price/Sales (Trailing)

10.1K

Price/Free Cashflow

-1.33

EYEN Price/Sales (Trailing)

EYEN Profitability

Operating Margin

-131.85%

Return on Equity

-1.8K%

Return on Assets

-123.86%

Free Cashflow Yield

-75.38%

EYEN Fundamentals

EYEN Revenue

Revenue (TTM)

3.8K

Rev. Growth (Qtr)

-99.85%

EYEN Earnings

Earnings (TTM)

-32.4M

Earnings Growth (Yr)

-89.92%

Earnings Growth (Qtr)

-36.81%

Breaking Down EYEN Revenue

Last 7 days

-2.6%

Last 30 days

38.9%

Last 90 days

-55.9%

Trailing 12 Months

-77.6%

How does EYEN drawdown profile look like?

EYEN Financial Health

Current Ratio

0.88

EYEN Investor Care

Shares Dilution (1Y)

34.09%

Diluted EPS (TTM)

-0.74

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	0	0	7.0M	3.8K
2021	5.0M	8.0M	11.0M	14.0M
2020	0	0	0	2.0M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Eyenovia Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 28, 2024	grant stuart m.	bought	98,000	0.98	100,000	-
Mar 19, 2024	grant stuart m.	bought	61,500	1.23	50,000	-
Mar 08, 2024	grant stuart m.	bought	16,911	1.578	10,717	-
Dec 04, 2023	rowe michael m	bought	6,650	1.36	4,890	chief executive officer
Nov 14, 2023	geltzeiler michael s	acquired	-	-	19,814	-
Sep 29, 2023	strahlman ellen r	bought	8,097	1.68	4,820	-
Sep 19, 2023	rowe michael m	bought	2,324	1.66	1,400	chief executive officer
Sep 15, 2023	rowe michael m	bought	1,989	1.75	1,137	chief executive officer
Aug 17, 2023	grant stuart m.	bought	56,100	1.87	30,000	-
Aug 16, 2023	grant stuart m.	bought	85,815	1.907	45,000	-

Which funds bought or sold EYEN recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	sold off	-100	-190,066	-	-%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-28.13	-6,791	3,509	-%
May 15, 2024	GOLDMAN SACHS GROUP INC	reduced	-19.04	-28,121	17,514	-%
May 15, 2024	DEUTSCHE BANK AG\	unchanged	-	-35,820	32,533	-%
May 15, 2024	STATE STREET CORP	added	6.37	-503,407	512,012	-%
May 15, 2024	MORGAN STANLEY	added	42.8	-68,810	144,165	-%
May 15, 2024	PRICE T ROWE ASSOCIATES INC /MD/	new	-	11,000	11,000	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	reduced	-8.35	-158,771	121,963	-%
May 15, 2024	BARCLAYS PLC	reduced	-46.11	-64,000	22,000	-%
May 15, 2024	Integrated Wealth Concepts LLC	unchanged	-	-13,861	12,493	-%

Are Funds Buying or Selling EYEN?

Are funds buying EYEN calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own EYEN

No. of Funds

Unveiling Eyenovia Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	armistice capital, llc	9.70%	4,378,000	SC 13G
Feb 13, 2023	eshelman fredric n	4.7%	1,708,548	SC 13D/A
Jan 24, 2023	ianchulev tsontcho	6.3%	2,257,422	SC 13D/A
Feb 08, 2022	grant stuart m.	18.75%	5,452,554	SC 13D/A
Dec 27, 2021	grant stuart m.	18.47%	5,416,524	SC 13D/A
Aug 24, 2021	yoshida shuhei	6.8%	1,751,900	SC 13D/A
Jun 10, 2021	grant stuart m.	18.59%	4,992,870	SC 13D/A
Nov 25, 2020	ianchulev tsontcho	7.2%	1,837,611	SC 13D/A
Nov 13, 2020	grant stuart m.	19%	4,897,178	SC 13D/A
Aug 28, 2020	ianchulev tsontcho	8.9%	2,280,739	SC 13D/A

Recent SEC filings of Eyenovia Inc

View All Filings

Date Filed	Form Type	Document
May 16, 2024	424B5	Prospectus Filed
May 16, 2024	8-K	Current Report
May 15, 2024	10-Q	Quarterly Report
May 15, 2024	8-K	Current Report
May 06, 2024	ARS	ARS
May 03, 2024	DEF 14A	DEF 14A
Apr 26, 2024	10-K/A	Annual Report
Apr 23, 2024	PRE 14A	PRE 14A
Apr 10, 2024	424B5	Prospectus Filed
Apr 10, 2024	8-K	Current Report

Peers (Alternatives to Eyenovia Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Eyenovia Inc News

Latest updates

Eyenovia Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)								(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4
Revenue	-99.9%	5.00	3,337	6,668	10,000	-	2,000	2,000	-
Cost Of Revenue	92.9%	5.00	3.00	1.00	-	-	800	800	-
Gross Profit	-	-	-	-	10,000	-	1,200	1,200	-
Operating Expenses	37.5%	10,267	7,467	6,520	6,947	5,925	5,982	6,567	5,407
S&GA Expenses	-100.0%	-	3,402	2,942	3,655	2,373	2,297	2,244	1,957
R&D Expenses	9.0%	4,432	4,065	3,578	3,292	3,552	3,685	4,323	3,450
Interest Expenses	-0.3%	679	681	679	185	119	78.00	5.00	2.00
Net Income	-36.8%	-10,900	-7,967	-7,338	2,983	-5,568	-4,841	-5,351	-4,206
Net Income Margin	-18.9%	-8.56	-7.20	-3.63*	-0.91*	-1.82*	-2.44*	-3.93*	-9.88*
Free Cashflow	-54.7%	-10,005	-6,467	-6,421	-12,761	1,183	-5,603	-4,944	5,410

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-9.0%	26.00	29.00	35.00	29.00	29.00	31.00	31.00	36.00	40.00	32.00	25.00	31.00	29.00	34.00	26.00	11.00	15.00	15.00	19.00	10.00	15.00
Current Assets	-30.2%	14.00	21.00	27.00	23.00	25.00	28.00	29.00	26.00	30.00	22.00	23.00	29.00	28.00	33.00	25.00	11.00	15.00	14.00	19.00	10.00	15.00
Cash Equivalents	-46.3%	8.00	15.00	21.00	17.00	18.00	23.00	17.00	22.00	27.00	27.00	14.00	27.00	25.00	28.00	23.00	10.00	14.00	14.00	18.00	9.00	14.00
Inventory	3100.3%	4.00	0.00	0.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net PPE	-6.5%	3.00	3.00	4.00	4.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Liabilities	23.1%	24.00	20.00	19.00	19.00	13.00	14.00	11.00	12.00	10.00	11.00	21.00	22.00	17.00	19.00	7.00	3.00	3.00	3.00	2.00	2.00	3.00
Current Liabilities	72.7%	16.00	10.00	7.00	4.00	5.00	5.00	11.00	12.00	10.00	11.00	21.00	15.00	16.00	18.00	7.00	3.00	3.00	3.00	2.00	2.00	3.00
Shareholder's Equity	-79.8%	2.00	9.00	16.00	11.00	16.00	17.00	20.00	24.00	30.00	20.00	4.00	9.00	12.00	15.00	19.00	8.00	12.00	12.00	16.00	8.00	12.00
Retained Earnings	-7.5%	-156	-145	-137	-130	-123	-118	-112	-104	-97.56	-90.22	-93.20	-87.63	-82.79	-77.44	-73.23	-68.14	-63.12	-57.67	-52.43	-47.78	-42.45
Additional Paid-In Capital	2.4%	158	154	153	141	140	135	132	128	127	111	97.00	97.00	95.00	93.00	92.00	76.00	75.00	69.00	69.00	55.00	55.00
Shares Outstanding	4.0%	47.00	46.00	43.00	38.00	38.00	37.00	35.00	34.00	30.00	28.00	26.00	26.00	25.00	25.00	-	-	-	-	-	-	-
Float	-	-	-	-	88.00	-	-	-	53.00	-	-	-	113	-	-	-	32.00	-	-	-	31.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-56.5%	-9,891	-6,322	-5,840	-4,714	-6,958	-5,405	-6,816	-4,699	-8,184	-12,700	1,700	-5,300	-4,600	5,469	-1,936	-3,998	-5,917	-4,020	-3,858	-5,143	-5,896
Share Based Compensation	-4.5%	546	572	613	494	819	891	929	1,037	909	814	777	637	657	656	610	633	584	578	477	424	1,033
Cashflow From Investing	21.4%	-114	-145	-1,703	-1,284	-838	-311	-163	-191	-207	-453	-517	-303	-344	-59.21	-69.80	-38.31	-93.93	-123	-43.48	-	-
Cashflow From Financing	410.0%	3,133	614	10,778	5,001	3,400	3,307	2,872	-318	15,646	12,291	-188	7,903	1,453	97.00	14,685	567	5,515	-	12,959	68.00	484

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

EYEN Income Statement

2024-03-31

Condensed Statements of Operations - USD ($)	3 Months Ended
Condensed Statements of Operations - USD ($)	Mar. 31, 2024	Mar. 31, 2023
Operating Income
Revenue	$ 4,993
Cost of revenue	(4,993)
Operating Expenses:
Research and development	4,431,601	$ 2,521,950
General and administrative	3,835,223	2,936,886
Reacquisition of license rights	2,000,000
Total Operating Expenses	10,266,824	5,458,836
Loss From Operations	(10,266,824)	(5,458,836)
Other Income (Expense):
Other (expense) income , net	(97,558)	70,993
Interest expense	(678,658)	(454,003)
Interest income	120,939	102,480
Total Other Expense	(655,277)	(280,530)
Net Loss	$ (10,922,101)	$ (5,739,366)
Net Loss Per Share
Net Loss Per Share - Basic	$ (0.23)	$ (0.15)
Net Loss Per Share - Diluted	$ (0.23)	$ (0.15)
Weighted Average Number of Common Shares Outstanding
Shares Outstanding - Basic	46,606,790	37,410,587
Shares Outstanding - Diluted	46,606,790	37,410,587

EYEN Balance Sheet

2024-03-31

Condensed Balance Sheets - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Current Assets
Cash and cash equivalents	$ 7,976,106	$ 14,849,057
Inventories	3,513,860	109,798
Deferred clinical supply costs	846,301	4,256,793
License fee and expense reimbursements receivable	88,045	123,833
Security deposits, current	1,506	1,506
Prepaid expenses and other current assets	2,025,267	1,365,731
Total Current Assets	14,451,085	20,706,718
Property and equipment, net	3,155,710	3,374,384
Security deposits, non-current	197,168	197,168
Intangible assets	6,122,945	2,122,945
Operating lease right-of-use asset	1,538,814	1,666,718
Equipment deposits	711,441	711,441
Total Assets	26,177,163	28,779,374
Current Liabilities:
Accounts payable	2,145,272	1,753,172
Accrued compensation	828,286	1,658,613
Accrued expenses and other current liabilities	4,751,755	287,928
Operating lease liabilities - current portion	579,585	501,250
Notes payable - current portion, net of debt discount of $621,712 and $503,914 as of March 31, 2024 and December 31, 2023, respectively	8,155,025	5,329,419
Total Current Liabilities	16,459,923	9,530,382
Operating lease liabilities - non-current portion	1,140,231	1,292,667
Notes payable - non-current portion, net of debt discount of $200,711 and $448,367 as of March 31, 2024 and December 31, 2023, respectively	2,103,456	4,355,800
Convertible notes payable - net of debt discount of $344,219 and $398,569 as of March 31, 2024 and December 31, 2023, respectively	4,655,781	4,601,431
Total Liabilities	24,359,391	19,780,280
Commitments and contingencies (Note 8)
Stockholders' Equity:
Preferred stock, $0.0001 par value, 6,000,000 shares authorized; 0 shares issued and outstanding as of March 31, 2024 and December 31, 2023
Common stock, $0.0001 par value, 90,000,000 shares authorized; 47,386,349 and 45,553,026 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	4,738	4,555
Additional paid-in capital	158,226,694	154,486,098
Accumulated deficit	(156,413,660)	(145,491,559)
Total Stockholders' Equity	1,817,772	8,999,094
Total Liabilities and Stockholders' Equity	$ 26,177,163	$ 28,779,374

About Eyenovia Inc

Eyenovia, Inc., a pre-commercial ophthalmic company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. It focuses on developing clinical microdosing of formulations of ophthalmic pharmaceutical agents using its Optejet branded targeted ocular delivery system. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi in rest of Asia. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is headquartered in New York, New York.

CEO	Mr. Michael M. Rowe
WEBSITE	eyenovia.com
INDUSTRY	Biotechnology
EMPLOYEES	41

Eyenovia Inc Frequently Asked Questions

What is the ticker symbol for Eyenovia Inc? What does EYEN stand for in stocks?

EYEN is the stock ticker symbol of Eyenovia Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Eyenovia Inc (EYEN)?

As of Fri May 17 2024, market cap of Eyenovia Inc is 38.22 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of EYEN stock?

You can check EYEN's fair value in chart for subscribers.

What is the fair value of EYEN stock?

You can check EYEN's fair value in chart for subscribers. The fair value of Eyenovia Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Eyenovia Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for EYEN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Eyenovia Inc a good stock to buy?

The fair value guage provides a quick view whether EYEN is over valued or under valued. Whether Eyenovia Inc is cheap or expensive depends on the assumptions which impact Eyenovia Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for EYEN.

What is Eyenovia Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, EYEN's PE ratio (Price to Earnings) is -1.18 and Price to Sales (PS) ratio is 10.09 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. EYEN PE ratio will change depending on the future growth rate expectations of investors.